DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Tremelimumab
Tremelimumab
Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
Remarkably Similar CTLA-4 Binding Properties of Therapeutic Ipilimumab and Tremelimumab Antibodies
New Biological Therapies: Introduction to the Basis of the Risk of Infection
ESCMID Online Lecture Library @ by Author
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Tables-Of-Phase-3-Mabs.Pdf
The Two Tontti Tudiul Lui Hi Ha Unit
Antibodies to Watch in 2021 Hélène Kaplona and Janice M
Structural Basis for Cancer Immunotherapy by the First-In-Class
Antibodies for the Treatment of Brain Metastases, a Dream Or a Reality?
Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
Final Efficacy Results of A3671009
Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Induc
Tremelimumab Study Code D419AC00001 Version 08 Date 09 January 2018
New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies
INN Working Document 05.179 Update 2011
Recent Biotherapies and Infections
(INN) for Biological and Biotechnological Substances
Top View
Biosimilar Antibodies & ELISA Kits
Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab
IMFINZI, INN-Durvalumab
WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
Anti-Drug Antibodies Against Immune
Rechallenge Patients with Immune Checkpoint Inhibitors Following Severe Immune-Related Adverse Events: Review of the Literature and Suggested Prophylactic Strategy
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
WO 2019/028191 Al 07 February 2019 (07.02.2019) W !P O PCT
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Antibodies Nima Sanai
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Tremelimumab As Second-Line Or Third-Line Treatment in Relapsed Malignant Mesothelioma
Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory Or Relapsed Melanoma
Astrazeneca Clinical Programmes Summary
Specialty Pipeline MONTHLY UPDATE
Is There Still a Role for Tremelimumab in the Treatment of Cancer?
A View Into Upcoming Specialty & Traditional Drugs
Progressive Hypoventilation Due to Mixed CD8+ and CD4+ Lymphocytic Polymyositis Following Tremelimumab - Durvalumab Treatment Sooraj John1, Scott J
Inside:Financings Roundup
Phage Display Technology As a Powerful Platform for Antibody Drug Discovery
Side Effect Profiles
Tremelimumab and MEDI4736 (Durvalumab) Study Code D4884C00001 Version 4.0 Date 13 Sep 2018
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances 2009
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Ph-Responsive Antibodies for Therapeutic Applications
Clinical Research Booklet
Safety and Efficacy of Durvalumab with Or Without Tremelimumab In
2020 Medicines in Development for Children
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
Clinical Trials Appendix Q2 2015 Results Update
An Anti-CTLA4 Monoclonal Antibody, in Patients with Refractory Metastatic Colorectal Cancer
Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
(INN) for Biological and Biotechnological Substances
Structure of CTLA-4 Complexed with a Ph-Sensitive Cancer
Thalidomide - Wikipedia, the Free Encyclopedia
Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers
Infliximab Associated with Faster Symptom Resolution Compared with Corticosteroids Alone for the Management of Immune-Related Enterocolitis Daniel H
Immuno-Imaging to Predict Treatment Response in Infection, Inflammation and Oncology
Immune Checkpoint Inhibitor-Induced Myasthenia Gravis
Part III the Delicate Balance of the Immune System Between Tolerance
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Dexamethasone to Reduce Stem Cell Accumulation in the Spleen
Antidrug Antibodies Against Immune
Efficacy and Tolerability of Tremelimumab in Locally Advanced Or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy
Publication Agenda CHMP 09-12 December 2019 CHMP
ACR Investor Science Conference Call Transcript PDF 206KB